Medical devices, healthcare technology and the business of care
510(k) clearance · K253316

PhAST instrument and PhAST Blood Culture Gram-negative Panel

Phast Corp. · Decision date Jun 26, 2026

FDA DECISIONK253316

What did the FDA decide?

FDA records K253316 as a 510(k) premarket notification, with a decision dated Jun 26, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Jun 26, 2026

FDA source record

Regulatory record facts

Identifier
K253316
Regulatory pathway
510(k) premarket notification
Applicant
Phast Corp.
Product code
SAN
Decision code
SESE
Decision date
Jun 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Automated Antimicrobial Susceptibility Test System For Positive Blood Culture Samples.

Applicant
Phast Corp.
Product code
SAN
FDA device class
2

FDA decision timeline

  1. K253316 received

    Application receipt date recorded by FDA.

  2. K253316 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code SAN

Product / regulatory recordCompanyPathwayDecision dateSource
BIOMERIEUX, Inc.510(k) clearanceJul 8, 2026FDA
Q-Linea AB510(k) clearanceApr 15, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Phast Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Boston, MA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records